Quarterly report pursuant to Section 13 or 15(d)

SCHEDULE OF ACQUIRED ASSETS IDENTIFIABLE INTANGIBLE ASSETS AND CERTAIN ASSUMED LIABILITIES (Details)

v3.22.2
SCHEDULE OF ACQUIRED ASSETS IDENTIFIABLE INTANGIBLE ASSETS AND CERTAIN ASSUMED LIABILITIES (Details) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2022
Dec. 31, 2021
Jun. 30, 2021
Dec. 31, 2020
Fair value of assets acquired and (liabilities assumed):        
Goodwill $ 8,079 $ 2,068 $ 2,068 $ 2,068
Kind Therapeutics USA LLC. [Member]        
Fair value of consideration transferred:        
Cash paid at closing 10,128      
Release of escrow 2,444      
Severance paid from escrow 556      
Less cash acquired (2,310)      
Net cash consideration 10,818      
Note payable 5,634      
Write-off accounts receivable 658      
Write-off of deferred accounts receivable 842      
Total fair value of consideration transferred 17,952      
Fair value of assets acquired and (liabilities assumed):        
Current assets, net of cash acquired 5,047      
Property and equipment 622      
Goodwill 6,011      
Current liabilities (511)      
Total fair value of assets acquired and (liabilities assumed) 17,952      
Kind Therapeutics USA LLC. [Member] | Trademarks and Trade Names [Member]        
Fair value of assets acquired and (liabilities assumed):        
Non-compete agreements 2,041      
Kind Therapeutics USA LLC. [Member] | Licenses and Customer Base [Member]        
Fair value of assets acquired and (liabilities assumed):        
Non-compete agreements 4,700      
Kind Therapeutics USA LLC. [Member] | Noncompete Agreements [Member]        
Fair value of assets acquired and (liabilities assumed):        
Non-compete agreements $ 42